---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-010164"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:02.471533+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response

## Summary
- Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
- PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.
- Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).
- FDA engagement for next-stage clinical development targeted for Q2 2026.
- Cash and equivalents projected to sustain operations into H1 2027.

## SEC filing metadata
- accession: 0001437749-26-010164
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926010164/0001437749-26-010164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926010164/phio20260326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-010164
- JSON: https://secwatch.observer/filing/0001437749-26-010164.json
- Plain text: https://secwatch.observer/filing/0001437749-26-010164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.